cells

COMBINING TO CURE

Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.

We’re combining
therapeutic strategies

to activate the immune system to recognize and eradicate cancer, which we believe has the potential to achieve cures that have eluded medicine for decades.

We’re combining
our expertise

across scientific disciplines to discover innovative, best-in-class medicines and to design combination therapies guided by specific biologic profiles of cancer.

We’re combining with the medical community

and with patients and their caregivers to facilitate participation in our clinical trials and bring breakthrough medicines to patients faster.

Arcus clinical trials are currently enrolling

Join forces with us on our mission to defeat cancer

Read our latest press releases and announcements

Media Highlights

Media Highlight Image

Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

May 27, 2020

CLINICAL PIPELINE

Indication View
Molecule View
Indication
Line
Regimena,b
Phase 1
Phase 1b
Randomized Phase 2
Indication:

NSCLC

Regimen:

dom + zim ± etruma

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + zim + carbo/pem

Phase 1
Phase 1b
Randomized Phase 2
Indication:

mCRPC

Regimen:

etruma + zim + enza

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + zim + doce

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + zim

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + AB680 ± zim

Phase 1
Phase 1b
Randomized Phase 2
Indication:

CRC

Regimen:

etruma + rego + atezo

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + FOLFOX

Phase 1
Phase 1b
Randomized Phase 2
Indication:

PDAC

Regimen:

etruma + atezo + gem/nab-pac

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

AB680 + zim + gem/nab-pac

Phase 1
Phase 1b
Randomized Phase 2
Indication:

TNBC

Regimen:

etruma + PLD

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + IPI-549 + PLD||

Phase 1
Phase 1b
Randomized Phase 2
Indication:

Pan-Tumor

Regimen:

zim monotherapy§

Phase 1
Phase 1b
Randomized Phase 2
Moleculea,b
Indication
Line
Regimen
Phase 1
Phase 1b
Phase 2
Molecule:

Etrumadenant
(ETRUMA)

Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule

Indication:

CRPC

Regimen:

etruma + zim

Phase 1
Phase 1b
Phase 2
Indication:

CRPC

Regimen:

etruma + zim ± (AB680 or enza or doce)

Phase 1
Phase 1b
Phase 2
Indication:

CRC

Regimen:

etruma + rego + atezo

Phase 1
Phase 1b
Phase 2
Indication:

CRC

Regimen:

etruma + FOLFOX

Phase 1
Phase 1b
Phase 2
Indication:

NSCLC

Regimen:

dom + zim + carbo/pem

Phase 1
Phase 1b
Phase 2
Indication:

NSCLC

Regimen:

dom + zim ± etruma

Phase 1
Phase 1b
Phase 2
Indication:

PDAC

Regimen:

etruma + atezo + gem/nab-pac

Phase 1
Phase 1b
Phase 2
Indication:

TNBC

Regimen:

etruma + PLD

Phase 1
Phase 1b
Phase 2
Indication:

TNBC

Regimen:

etruma + IPI-549 + PLD||

Phase 1
Phase 1b
Phase 2
Molecule:

AB680

CD73 Inhibitor Small Molecule

Indication:

PDAC

Regimen:

AB680 + zim + gem/nab-pac

Phase 1
Phase 1b
Phase 2
Molecule:

Domvanalimab
(DOM)

Anti-TIGIT Antibody

Indication:

NSCLC

Regimen:

dom + zim ± etruma

Phase 1
Phase 1b
Phase 2
Indication:

Multiple Cancer Types

Regimen:

dom + zim

Phase 1
Phase 1b
Phase 2
Molecule:

Zim­ber­eli­mab
(ZIM)

Anti-PD-1 Antibody

Indication:

Biomarker Selected (tumor-type agnostic)

Regimen:

All lines§

Phase 1
Phase 1b
Phase 2


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
AB680: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; TNBC=triple-negative breast cancer;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Clinical collaboration with Genentech, Member of the Roche Group.
||Clinical collaboration with Infinity Pharmaceuticals.
§Clinical collaboration with Strata Oncology.


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
AB680: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; TNBC=triple-negative breast cancer;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Clinical collaboration with Genentech, Member of the Roche Group.
||Clinical collaboration with Infinity Pharmaceuticals.
§Clinical collaboration with Strata Oncology.

DISCOVERY PIPELINE

icon

HIF-2𝛂 Inhibitor

Transcription factor

Cancer cell intrinsic target; potential non-oncology indications

HIF-2α is a master transcriptional regulator of multiple genes involved in tumor progression.1

icon

AXL Inhibitor

Tyrosine kinase

Cancer cell intrinsic target

AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.2

icon

PI3Kγ Inhibitor

Glycolipid kinase

Immune (TAM, MDSC) target

PI3Kγ is required for the immunosuppressive activity of tumor-infiltrating macrophages and myeloid-derived suppressor cells.3

icon

PAK4 Inhibitor

Serine kinase

Cancer cell intrinsic target

PAK4 overexpression is responsible for T cell exclusion from immune desert tumors.4

icon

Anti-TIM-3 Antibody

Immune Checkpoint

Cancer cell intrinsic and immune (T cell) target

TIM-3 is an immune checkpoint highly overexpressed by leukemic cells (eg, MDS, AML) and exhausted T cells.5

AML, acute myeloid leukemia; HIF-2𝛂, hypoxia-inducible factor 2-alpha; MDS, myelodysplastic syndromes; PAK-4, p21-activated kinase 4; PI3Kγ, phosphatidylinositol 3-kinase-gamma; TIM-3, T cell immunoglobulin and mucin-domain containing-3.

References: 1. Murugesan T, Rajajeyabalachandran G, Kumar S, Nagaraju S, Kumar S. Targeting HIF-2α as therapy for advanced cancers. Drug Discov Today. 2018;23(7):1444-1451. 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369. 3. Foubert P, Kaneda MM, Varner JA. PI3Kγ activates integrin α4 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol Res. 2017;5(11):957-968. 4. Abril-Rodriguez G, Torrejon DY, Liu W, et al. PAK4 inhibition improves PD-1 blockade immunotherapy. Nature Cancer. 2020;1:46-58. 5. Toshio A, Tamura H, Ishibashi M, et al. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget. 2017;8(51):88904-88917.